Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03343535 · ClinicalTrials.gov registry record · NA
OCS Lung System EXPAND II Trial
A NA study, sponsored by TransMedics.
- Terminated
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT03343535: Clinical Trial NA study, sponsored by TransMedics.
NCT03343535 is a NA study that was terminated before completion, run by TransMedics. The registered enrollment target is 46 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03343535, a NA study, was terminated before completion, sponsored by TransMedics.
- TERMINATED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
To evaluate the safety and effectiveness of the OCS™ Lung System to recruit, preserve and assess non-ideal donor lungs that may not meet current standard donor lung acceptance criteria for transplantation.
Primary Outcome
Patient survival at Day-30 post-transplantation or initial hospital discharge post-transplantation, whichever occurs later.
Interventions
- DEVICE OCS Lung Preservation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2018-03-12 |
| Est. Completion | 2022-07-06 |
| Phase | NA |
Why NCT03343535 stopped before completion
NCT03343535 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which OCS Lung Preservation is the first listed.
NCT03343535 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03343535 about?
NCT03343535 is a clinical study titled "OCS Lung System EXPAND II Trial". To evaluate the safety and effectiveness of the OCS™ Lung System to recruit, preserve and assess non-ideal donor lungs that may not meet current standard donor lung acceptance criteria for transplantation.
What is the current status of trial NCT03343535?
This trial is currently terminated. It is a NA study. The enrollment target is 46 participants. The study started on 2018-03-12. Estimated completion is 2022-07-06.
What interventions are being tested in trial NCT03343535?
The interventions under investigation include: OCS Lung Preservation (DEVICE).
Who is sponsoring clinical trial NCT03343535?
This trial is sponsored by TransMedics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03343535's enrollment target sits among peer trials
46 1402nd of 2000 higher than 590 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI